Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Farmacosmo SpAMIL:COSMO +1.93%34 Debt-to-EBITDA is 3.29 as of Dec. 2025, which is 35% below its 10-year median of 5.10. GuruFocus rates MIL:COSMO with a GF Score™ of 34/100 and a GF Value™ of €0.75 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Farmacosmo SpA ranks worse than 96.03% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Farmacosmo SpA's Debt-to-EBITDA or its related term are showing as below:
MIL:COSMO'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 5.1 Max: 21.46
Current: 21.46
During the past 6 years, the highest Debt-to-EBITDA Ratio of Farmacosmo SpA was 21.46. The lowest was 0.01. And the median was 5.10.
MIL:COSMO's Debt-to-EBITDA is ranked worse than 96.03% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.215
vs MIL:COSMO: 21.46
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Farmacosmo SpA Debt-to-EBITDA Related Terms
Farmacosmo SpA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Farmacosmo SpA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Farmacosmo SpA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farmacosmo SpA Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Farmacosmo SpA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Farmacosmo SpA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Farmacosmo SpA (MIL:COSMO) has a Debt-to-EBITDA of 3.29 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Farmacosmo SpA. This is 35% below median its historical median of 5.10. Over the past decade, Farmacosmo SpA's Debt-to-EBITDA has ranged from 0.01 to 21.46. According to the industry distribution chart, Farmacosmo SpA ranks #459 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 96%.
Is Farmacosmo SpA's Debt-to-EBITDA too high?
Farmacosmo SpA's current Debt-to-EBITDA of 3.29 is 35% below median its 10-year median of 5.10. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 21.46. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Farmacosmo SpA's value of 3.29 is 48.5% above this industry median. Based on the distribution chart, Farmacosmo SpA ranks #459 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Farmacosmo SpA has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Farmacosmo SpA's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Farmacosmo SpA ranks #459 out of 478 companies for Debt-to-EBITDA. This places Farmacosmo SpA in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. Farmacosmo SpA's value of 3.29 is 48.5% above this benchmark. Historically, Farmacosmo SpA's own Debt-to-EBITDA has ranged from 0.01 to 21.46 over the past decade. While the company's 10-year median is 5.10 vs. the industry median of 2.22, Farmacosmo SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Farmacosmo SpA's current Debt-to-EBITDA of 3.29 is 48.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Farmacosmo SpA. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farmacosmo SpA's current Debt-to-EBITDA is 3.29, which is 35% below median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farmacosmo SpA stock overvalued right now?
Based on GuruFocus' analysis, Farmacosmo SpA (MIL:COSMO) is currently considered Possible Value Trap. The stock's GF Value™ is €0.75, compared to a current price of €0.48 — trading 36.7% below its estimated fair value. The current Debt-to-EBITDA is 3.29, which is 35% below median its 10-year median of 5.10 and 48.5% above the Healthcare Providers & Services industry median of 2.22. Farmacosmo SpA's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Farmacosmo SpA (MIL:COSMO), the current Debt-to-EBITDA is 3.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Farmacosmo SpA (MIL:COSMO) Overvalued in 2026?
Based on GuruFocus' analysis, Farmacosmo SpA stock appears to be undervalued.
The current stock price of €0.48 is trading 36.7% below its estimated GF Value™ of €0.75.
GuruFocus considers Farmacosmo SpA to be Possible Value Trap.
Key valuation signals for MIL:COSMO:
Debt-to-EBITDA: 3.29 (35% below median its 10-year median of 5.10)
GF Value™: €0.75 vs. price of €0.48 (36.7% below fair value)
Industry Position: 48.5% above the Healthcare Providers & Services median (#459 of 478)
No single metric tells the full story. See the MIL:COSMO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Farmacosmo SpA is a wellness e-commerce company active in the Health, Pharma, and Wellness industry, authorized by the Italian Ministry of Health to sell pharmaceutical products online. In particular, the company offers parapharmaceutical products, vitamins and food supplements, dietetic products, medical devices, cosmetic products, personal hygiene products, hair care products, dental care products, skincare products, perfumes, home and baby items.
34GF Score
Get the complete analysis for MIL:COSMO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:COSMO has been successfully added to your 
